OncView Podcast: Genomic Testing in HR+ Breast Cancer to Guide Therapy in the Extended Adjuvant Setting

Podcast

In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD about the current role of genomic testing in HR-positive breast cancer.

As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.

In the video series, Gadi discussed the following:

To watch more videos in CancerNetwork’s OncView series, visit cancernetwork.com.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
Related Content
HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

Ariana Pelosci
June 2nd 2025
Article

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer

Caroline Seymour
June 1st 2025
Article

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty
June 1st 2025
Article

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.